A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.
BCG's Sylvain Duranton said companies should understand the risk of holding back too much in the "tokenmaxxing" era.
Combining BCG's Transformation Expertise with Google Cloud's AI to Drive Enterprise-Wide Agent Adoption LAS VEGAS, April 22, 2026 /PRNewswire/ -- Cloud Next '26 -- Boston Consulting Group (BCG) and ...
Preliminary findings were presented at the 2025 ASCO Genitourinary Cancers Symposium. 2 Investigators reported that 71% of ...
Stocktwits on MSN
IBRX stock in spotlight: ImmunityBio to unveil fresh Anktiva and BCG data next week
The findings could play a key role in guiding treatment choices, ImmunityBio said. ・ImmunityBio will present new research on intravesical recombinant BCG in patients who have not previously received ...
Boston Consulting Group (BCG) celebrated the launch of the 8th edition of Jeel Tamooh, its flagship program designed to ...
As organizations experiment with placing AI agents on org charts as “employees,” new research shows this framing has unintended consequences. In a large-scale experiment, anthropomorphizing AI reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results